Jan. 28 at 12:42 AM
$IMRX Reminder, median OS has not been reached yet after 13+ months! Benchmark is 8.5 months. This is good, it means more than 50% of the patients are STILL alive. To put that in perspective, we are seeing an over 53% increase in median overall survival… AND COUNTING!
Another reminder about this company: Cash runway until 2029, Sanofi private placement for
$25 million at
$9.23/share, Lilly agreement to test atebimetinib in combination with olomorasib, multiple recent insider purchases, tackling metastatic pancreatic cancer (considered graveyard for drugs), phase 3 trial to start mid year 2026 and released in 2028 (before cash runway is up), fda fast tracked, no debt, is an MEK inhibitor which mean it is able to be applied to 97% of ALL pancreatic cancer patients (very large %), potential to treat lung cancer and melanoma, and so much more!
